A comparative pharmacoeconomic analysis of the brentuximab vetodin in the treatment for relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma in patients older than 18 years.
Material and methods
Clinical and economic modeling was conducted. Four medical technologies were evaluated: brentuximab vetodin, high-dose chemotherapy, and brentuximab in combination with chemotherapy in two different regimens.
The strategies of brentuximab vetodin and its combinations were more effective than high-dose chemotherapy. Brentuximab vetodin monotherapy and sequential treatment with brentuximab vetodin and cytostatics were less expensive alternatives compared with high-dose chemotherapy followed by hematopoietic stem cell transplantation. ICER in terms of progression-free survival for the strategies of brentuximab vetodin and brentuximab vetodin in combination with chemotherapy in the combined regimen, remained below the society willingness-to-pay threshold. In terms of the budget impact analysis, brentuximab vetodin monotherapy, as well as combined therapy with cytostatics in a sequential mode, were the most preferred alternative. Results of the sensitivity analysis confirmed the conclusions of the main scenario.
Combination of brentuximab vetodin with classical chemotherapeutic agents increases the complete response rate and 2-year patients survival. Sequential treatment with brentuximab vetodin and high-dose chemotherapy is characterized by the lowest cost among all assessed systemic anaplastic large-cell lymphoma treatment technologies.
Pharmacoeconomic analysis, economic modeling, brentuximab, relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma.